drugset
drugset / Trial / NCT00840281

Cefprozil 500 mg Tablets Under Fasting Conditions

NCT00840281 ↗

Phase 1 Completed 38 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to compare the relative bioavailability of cefprozil 500 mg tablets (Teva Pharmaceuticals USA) with that of Cefzil® 500 mg tablets (Bristol-Myers Squibb) in healthy, non-smoking adults under fasting conditions.

Timeline

Start
2003-09
Primary completion
2003-09
Completion
2003-09

Outcome

Met primary endpoint

registry Ratio of the T/R geometric mean x 100 100 (90% CI 94.9 to 105) NCT00840281 ↗

registry Ratio of the T/R geometric mean x 100 101 (90% CI 98.6 to 103) NCT00840281 ↗

registry Ratio of the T/R geometric mean x 100 101 (90% CI 98.7 to 103) NCT00840281 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject CEFPROZIL ANHYDROUS, (E)- Small molecule 500 mg —

Indications

No indication recorded.